caseism

The Case of Synthroid (A) Case Solution & Answer

“The case tells the story of Synthroid its development in 1958, the first molecule of synthetic thyroxine for competition against generic equivalents in 2004. The case introduces students to the pharmaceutical industry, its practices, and some of the complexities and price choice of drug, drug manufacturers, insurance companies, physicians, pharmacists and patients when playing a role. also provides an introduction to hypothyroidism, symptoms and treatment. because Synthroid was they developed and presented before were fully established regulations and standards of identity FDA drug, it was difficult for competitors to get their certificates identical to Synthroid. Through a series of drug efforts with physicians, especially endocrinologists, the owners have managed to keep Synthroid 46 perception that Synthroid was particularly effective. In 2004, however, said more competitors bioequivalent to Synthroid products that pose a challenge of its own size, Abbott Laboratories FDA. Students revenues and / or profits in these difficult circumstances are invited to explore options to keep the volume of the unit drugs. The case is written in two parts. The (A) case presents the context of the history of medicine, the pharmaceutical industry and its marketing practices, and hypothyroidism and its treatment, and concluded in 2004 that traders face imminent challenge Abbott defending the company against competition from generic Synthroid. (B) describes this case Abbott actually has to maintain its share in the United States and outlines its strategy in India, a market without patent protection for pharmaceuticals. ”
by
Alice M. Tybout,
Julie Hennessy,
Natalie Fahey
Charlotte Snyder
Source: Kellogg School of Management
19 pages.
Date Posted: February 19, 2013. Prod #: KEL728-PDF-ENG
The case of Synthroid (A) Case Solution

Share This

LOOK FOR A FREE CASE STUDY SOLUTION

JUST REGISTER NOW AND GET 50% OFF ON EACH CASE STUDY